Analysts Set Bruker Co. (NASDAQ:BRKR) Price Target at $70.50

Shares of Bruker Co. (NASDAQ:BRKR) have earned a consensus rating of “Moderate Buy” from the eleven ratings firms that are currently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $70.50.

A number of research analysts have recently weighed in on the company. TD Cowen cut their price objective on Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research report on Wednesday, November 6th. The Goldman Sachs Group upgraded Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price objective for the company in a research report on Thursday, December 5th. Barclays cut their price objective on Bruker from $69.00 to $65.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Guggenheim reaffirmed a “buy” rating on shares of Bruker in a report on Friday, January 17th. Finally, Bank of America increased their price target on shares of Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a report on Friday, December 13th.

Institutional Trading of Bruker

Institutional investors have recently added to or reduced their stakes in the company. True Wealth Design LLC lifted its stake in Bruker by 4,636.4% in the third quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock worth $36,000 after purchasing an additional 510 shares during the last quarter. Eagle Bay Advisors LLC lifted its stake in Bruker by 2,324.1% in the fourth quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock worth $41,000 after purchasing an additional 674 shares during the last quarter. UMB Bank n.a. raised its stake in shares of Bruker by 37.5% during the fourth quarter. UMB Bank n.a. now owns 909 shares of the medical research company’s stock valued at $53,000 after acquiring an additional 248 shares in the last quarter. Values First Advisors Inc. bought a new stake in shares of Bruker during the third quarter valued at approximately $73,000. Finally, Capital Performance Advisors LLP bought a new stake in shares of Bruker during the third quarter valued at approximately $77,000. Institutional investors own 79.52% of the company’s stock.

Bruker Price Performance

NASDAQ BRKR opened at $50.82 on Friday. The business’s fifty day moving average price is $56.73 and its 200-day moving average price is $60.03. The stock has a market capitalization of $7.70 billion, a price-to-earnings ratio of 66.87, a PEG ratio of 2.16 and a beta of 1.16. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77. Bruker has a 1-year low of $48.07 and a 1-year high of $94.86.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. On average, equities analysts predict that Bruker will post 2.69 earnings per share for the current year.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.